Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.
THARROS is the first phase 3 RCT to evaluate an inhaled triple combination therapy for reduction of adverse cardiopulmonary events in people with COPD, says AstraZeneca.
A PDUFA date of June 27, 2024 has been set for approval of a 6th dupilimab indication - as add-on therapy for individuals with COPD and eosinophilic inflammation.